Dr. Stephen De Rosa develops assays to characterize our immune responses to vaccination against pathogens including HIV, tuberculosis, SARS-CoV-2 and malaria. In particular, he develops, optimizes and validates flow cytometry-based assays that detect whether a vaccine triggers responses from T and B cells, critical immune cells that can be engaged by a vaccine to protect against future infection and disease. These assays are essential to assessing a vaccine’s protective potential, and De Rosa’s work supports large vaccine trial networks, including the HIV Vaccine Trials Network (HVTN), that test vaccines around the globe.
MD, Stanford University, 1990
BS, Columbia Universtiy School of Engineering & Applied Sciences, 1983
Immunology of HIV, SARS-CoV-2, malaria, turbulosis related to vaccination; flow cytometry as a tool to characterize antigen-specific T and B cells and other immune cells
Cellular immunity characterization in HIV Vaccine Trials Network (HVTN) clinical trials; providing immunological consultation through the UW/Fred Hutch Center for AIDS Research (CFAR).
— Dr. Stephen De Rosa
